Recursion Pharmaceuticals (RXRX) Expected to Announce Quarterly Earnings on Tuesday

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Recursion Pharmaceuticals to post earnings of ($0.44) per share and revenue of $19.04 million for the quarter.

Recursion Pharmaceuticals Trading Down 10.3 %

NASDAQ RXRX traded down $1.07 during mid-day trading on Friday, reaching $9.28. 31,310,150 shares of the stock were exchanged, compared to its average volume of 25,887,924. The business's fifty day simple moving average is $7.56 and its 200 day simple moving average is $7.02. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The stock has a market capitalization of $3.63 billion, a PE ratio of -6.07 and a beta of 0.86. Recursion Pharmaceuticals has a 1-year low of $5.60 and a 1-year high of $15.74.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RXRX. KeyCorp lowered their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a research report on Wednesday, January 8th. Needham & Company LLC reissued a "buy" rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.